CBAY - CymaBay Therapeutics announces departure of chief commercial officer Lewis Stuart
2023-12-21 16:23:09 ET
More on CymaBay Therapeutics
- Circling Back On CymaBay Therapeutics
- CymaBay Therapeutics, Inc. (CBAY) Q3 2023 Earnings Call Transcript
- CymaBay applies for FDA approval of liver disease drug seladelpar
- CymaBay spikes ahead of Phase 3 data for lead asset
- Seeking Alpha’s Quant Rating on CymaBay Therapeutics
For further details see:
CymaBay Therapeutics announces departure of chief commercial officer Lewis Stuart